Superior clinical benefit of brentuximab vedotin in mycosis fungoides versus physician's choice irrespective of CD30 level or large cell transformation status in the phase 3 ALCANZA study Meeting Abstract
| Authors: | Kim, Y. H.; Prince, H. M.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Bechter, O.; Sanches, J. A.; Stadler, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Eradat, H.; Pinter-Brown, L. C.; Ortiz-Romero, P. L.; Akilov, O. E.; Trotman, J.; Taylor, K.; Weichenthal, M.; Walewski, J.; Fisher, D. C.; McNeeley, M.; Gru, A. A.; Wang, Y.; Palanca-Wessels, M. C.; Lisano, J.; Li, M.; Lin, H. M.; Little, M.; Trepicchio, W. L.; Dummer, R. |
| Abstract Title: | Superior clinical benefit of brentuximab vedotin in mycosis fungoides versus physician's choice irrespective of CD30 level or large cell transformation status in the phase 3 ALCANZA study |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837605023 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-112847 |
| Notes: | Meeting Abstract: 1646 -- Source: Wos |
